Filing Details
- Accession Number:
- 0001209191-17-056551
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-10-10 19:04:09
- Reporting Period:
- 2017-10-05
- Accepted Time:
- 2017-10-10 19:04:09
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1377121 | Protagonist Therapeutics Inc | PTGX | Pharmaceutical Preparations (2834) | 980505495 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1675878 | S. Richard Shames | C/O Protagonist Therapeutics, Inc. 7707 Gateway Boulevard, Suite 140 Newark CA 94560 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2017-10-05 | 2,017 | $4.21 | 2,017 | No | 4 | M | Direct | |
Common Stock | Disposition | 2017-10-05 | 2,017 | $19.00 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2017-10-05 | 2,017 | $0.00 | 2,017 | $4.21 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
36,802 | 2026-04-29 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 9, 2017.
- The option vests over a four-year period, with 1/4th of the shares subject to the option vesting on the one year anniversary of the vesting commencement date, and 1/36th of the remaining shares subject to the option vesting each month, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date.